For dispensations outside the benefit, both obesity (71.1%) and obesity without a T2DM diagnosis (68.1%) dominated overall and showed an increase of 31% and 76%, respectively, among incident GLP-1 RA patients between 2019 and 2023. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.